Journal For Clinical Studies
Journal For Clinical Studies

SEARCH

MEDIA PACK
NEWS

MENU

Current Edition

 
Belzutifan

Merck’s Welireg scores FDA nod in cancers spurred by rare disease—and its label is broader than expected

Merck’s $1.1 billion bet on Peloton Therapeutics is starting to pay off. Belzutifan, one of the most lucrative assets Merck picked up through its 2019 …

18 August 2021 Regional News Belzutifan central nervous system
Continue Reading →
 
jcs-white

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Twitter Linkedin
Journal For Clinical Studies © 2022, All Rights Reserved – Powered by Teksyte